1. Irreversible Electroporation Margin Accentuation in Pancreaticoduodenectomy: A Propensity Score Matching Analysis.
- Author
-
Lim JS, Heard J, Brant N, Malo J, Kong J, Osman H, Buell J, and Jeyarajah DR
- Subjects
- Humans, Male, Female, Aged, Survival Rate, Middle Aged, Follow-Up Studies, Prognosis, Retrospective Studies, Neoplasm Recurrence, Local pathology, Pancreaticoduodenectomy methods, Pancreatic Neoplasms surgery, Pancreatic Neoplasms pathology, Propensity Score, Margins of Excision, Electroporation methods, Adenocarcinoma surgery, Adenocarcinoma pathology
- Abstract
Background: Margin accentuation using irreversible electroporation (MA-IRE) improves recurrence and overall survival (OS) in pancreatic cancer patients; however, there have been limited outcome comparisons to similarly risked patients who did not receive MA-IRE., Methods: Patients with borderline resectable or locally advanced pancreatic adenocarcinoma who underwent a pancreaticoduodenectomy (PD) between 2017 and 2022 were included. Those who did not receive neoadjuvant chemotherapy for major vessel involvement were excluded. One-to-one propensity score matching (PSM) was used to match the MA-IRE group with the corresponding non-MA-IRE control group with similar risk factors., Results: A total of 36 patients were included in this study. Seventeen (47.2%) patients who underwent MA-IRE matched with 19 control patients (52.8%) with similar risk factors who did not have MA-IRE. Before matching, OS and disease-free survival (DFS) were comparable between the MA-IRE and non-MA-IRE groups. After matching, the MA-IRE group showed improved OS (746 vs. 509 days, hazard ratio 0.313; p = 0.034) compared with the non-MA-IRE group. DFS (p = 0.768), negative margin status (p = 0.317), and 30-day complication rates (p = 1.000) remained statistically different between the groups., Conclusions: MA-IRE in PD results in longer OS but does not impact margin status, DFS, or postoperative complication rates in our cohort. These findings suggest that MA-IRE is safe and potentially promotes immune cell activation rather than upfront margin mitigation., (© 2024. Society of Surgical Oncology.)
- Published
- 2024
- Full Text
- View/download PDF